Clene Inc. (NASDAQ:CLNN) Receives $33.25 Consensus Price Target from Brokerages

Clene Inc. (NASDAQ:CLNN) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $33.25.

Several research analysts have recently commented on the company. Weiss Ratings raised Clene from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Clene in a research report on Monday, May 4th. D. Boral Capital reiterated a “buy” rating and issued a $23.00 target price on shares of Clene in a research report on Monday, May 4th. Finally, Roth Capital reissued a “buy” rating on shares of Clene in a research note on Thursday, May 14th.

Clene Stock Performance

Clene stock opened at $5.85 on Friday. Clene has a fifty-two week low of $3.25 and a fifty-two week high of $13.50. The stock has a market cap of $74.76 million, a P/E ratio of -1.83 and a beta of 0.92. The firm’s fifty day moving average price is $6.13 and its 200-day moving average price is $5.69.

Clene (NASDAQ:CLNN) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.05). The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.05 million. Sell-side analysts predict that Clene will post -1.58 earnings per share for the current year.

Insider Buying and Selling at Clene

In related news, major shareholder Chidozie Ugwumba sold 73,296 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $6.20, for a total value of $454,435.20. Following the completion of the sale, the insider owned 103,417 shares in the company, valued at $641,185.40. The trade was a 41.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 193,649 shares of company stock worth $1,247,348. Company insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On Clene

A number of hedge funds have recently made changes to their positions in CLNN. SymBiosis Capital Partners LLC bought a new position in shares of Clene during the 4th quarter valued at $4,523,000. Scoggin Management LP boosted its position in Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after buying an additional 107,250 shares during the period. Ensign Peak Advisors Inc grew its stake in shares of Clene by 668.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after buying an additional 99,481 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock worth $482,000 after buying an additional 6,090 shares during the period. Finally, PEAK6 LLC purchased a new position in shares of Clene in the fourth quarter worth about $294,000. 23.28% of the stock is currently owned by institutional investors.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).